Tirzepatide added to ixekizumab for psoriasis and weight issues
Treatments studied
Part of Hormones & metabolism, Skin clinical trials.
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe plaque psoriasis diagnosed by a doctor.
- Your body mass index (BMI) is 30 or higher, or 27 to 29.9 with a weight-related condition like high blood pressure or type 2 diabetes.
- You have been taking ixekizumab for about 3 months (between 2 and 4 months) before starting tirzepatide.
- You are able to start tirzepatide within 30 days of your doctor's decision.
- You have not taken tirzepatide or similar drugs (like dulaglutide, liraglutide, or semaglutide) before.
- You do not have type 1 diabetes, certain thyroid conditions, or serious stomach problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.